Search results
12 sty 2023 · It is disheartening for parents to discover that their children have long-term cardiac dysfunction after being cured of life-threatening childhood cancers. As the number of childhood cancer survivors increases, early and late oncology-therapy-related cardiovascular complications continues to rise.
8 sty 2016 · The various cellular effects of these chemotherapy agents may ultimate result in cardiovascular manifestations in the form of left ventricular dysfunction, heart failure, hypertension, and atherosclerosis.
13 kwi 2021 · Among the growing number of cancer survivors, there is a notable increase in the prevalence of chemotherapy side-effects on the CV system [3]. CV diseases are among the main causes of long-term morbidity and mortality in cancer survivors [4, 5, 6].
Various ChT regimens are associated with a wide range of potential CV toxicities and in selected situations cardiac biomarkers may help detect or predict CV toxicities, particularly cardiomyopathy and/or heart failure (HF).
29 paź 2013 · Treatment-induced cardiovascular events associated with chemotherapy and radiotherapy include cardiomyopathy, conduction defects, myocardial infarction, hypertension, stroke, pulmonary oedema,...
14 mar 2020 · Pediatric heart failure is a complex, clinical and pathophysiologic syndrome that encompasses a diverse population of patients with congenital heart disease (CHD), cardiomyopathy, infectious and inflammatory diseases, oncologic processes, metabolic syndromes, renal failure, and malnutrition (1, 2).
28 mar 2018 · Cardiotoxicity resulting in heart failure (HF) is one of the most dreaded complications of cancer therapy that can significantly impact patient care and clinical outcomes. HF can occur as a consequence of cancer treatment–related cardiotoxicity secondary to chemotherapy (1, 2), radiation therapy (3) and biotherapy (4).
